The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program ...

In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode ...

Hospital and pharma groups have sharpened their spears for the rematch on 340B rebates.  | The administration's second stab ...

Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that would outweigh the program’s benefits.

AHA urges HRSA to axe 340B model that would cost hospitals over $1 billion annually and increase administrative burdens.

While it may be hard to believe, there is one issue in Washington that meets the above criteria: fixing the 340B program.

A new analysis from healthcare consulting firm Trilliant Health contains some grim news for people concerned about the plight ...

A federal court recently blocked the Trump administration from moving forward with a proposed pilot program that could have saved patients, taxpayers and employers billions of dollars. But fortunately ...

Add Yahoo as a preferred source to see more of our stories on Google. In a recent opinion piece, it was suggested the federal 340B Drug Pricing Program is contributing to rising employer health-care ...

Ravin Consultants announced today a leadership evolution that reflects the strength of its foundation and its long-term vision for the future of the 340B program. This press release features ...